PDF(Pubmed)
Abstract：
NK cells are cytotoxic innate immune cells involved in antitumor immunity, and they provide a treatment option for patients with acute myeloid leukemia (AML). In this issue of the JCI, Cubitt et al. investigated the role of CD8α, a coreceptor present on approximately 40% of human NK cells. IL-15 stimulation of CD8α- NK cells induced CD8α expression via the RUNX3 transcription factor, driving formation of a unique induced CD8α (iCD8α+) population. iCD8α+ NK cells displayed higher proliferation, metabolic activity, and antitumor cytotoxic function compared with preexisting CD8α+ and CD8α- subsets. Therefore, CD8α expression can be used to define a potential dynamic spectrum of NK cell expansion and function. Because these cells exhibit enhanced tumor control, they may be used to improve in NK cell therapies for patients with AML.
摘要：
NK细胞是参与抗肿瘤免疫的细胞毒性先天性免疫细胞,它们为急性髓系白血病（AML）患者提供了治疗选择。在本期JCI中，Cubitt等人。研究了CD8α的作用，共受体存在于大约40%的人NK细胞上。IL-15刺激CD8α-NK细胞通过RUNX3转录因子诱导CD8α表达，驱动形成独特的诱导CD8α(iCD8α+)群体。iCD8α+NK细胞表现出更高的增殖，代谢活动，与先前存在的CD8α+和CD8α-亚群相比，具有抗肿瘤细胞毒性功能。因此,CD8α表达可用于定义NK细胞扩增和功能的潜在动态谱。因为这些细胞表现出增强的肿瘤控制，它们可用于改善AML患者的NK细胞治疗.
